To print: Select File and then Print from your browser's menu

Title: Dialysis Graft Infections Curbed With Cryopreserved Femoral Vein

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12453687&dopt=Abstract

Cardiovasc Surg 2002; Dec;10(6):561-5. "Hemodialysis graft infections treated with cryopreserved femoral vein."
12/10/2002 04:30:47 PM
By Anne MacLennan

Cryopreserved femoral vein is useful in the treatment of patients with infected haemodialysis grafts, researchers in the United States have found. The absence of infection after implantation around an infected area shows promise for salvaging an angioaccess site that would otherwise have been abandoned, reports this prospective study from the Department of Surgery, The Atlanta Medical Center, Atlanta, Georgia. Treatment of haemodialysis graft infections after implantation has been linked with prolonged hospitalisation and wound care. Objective of these researchers was to evaluate the use of cryopreserved femoral vein (CFV) for angioaccess in such infections. Dr J H Matsuura and colleagues placed 43 CFV arteriovenous grafts (AVGs) in 43 patients with prosthetic AVG infections. Of these CFV AVGs, 32 were constructed adjacent to the infected AVG using a parallel tunnel tract. Eleven of them were placed into the infected field. The patients were then all prospectively followed at three-month intervals for graft complications and recurrent infections, for a mean follow-up period of 418 days. During this follow-up, there was one recurrent infection (2.3 percent), while the one-year primary and secondary graft patency rates were, respectively, 42 percent and 68 percent. The two-year primary and secondary patency rates were 31 percent and 63 percent, respectively.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12453687&dopt=Abstract

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.